Pharmaceuticals - BioReview (Page 5)

Biotechnology

Denali's Blood-Brain Barrier Breakthrough: Hunter Syndrome Therapy Achieves NEJM Publication and Awaits Historic FDA Decision

Denali Therapeutics' tividenofusp alfa achieves historic NEJM publication as the first brain-penetrant enzyme replacement therapy for Hunter syndrome, with FDA decision expected by April 5, 2026.

Pharmaceuticals

Novo Nordisk's Wegovy Pill Approval Marks Pivotal Moment in Obesity Treatment Revolution

Novo Nordisk achieved a critical milestone in the final days of 2025 when the FDA approved the first oral GLP-1 medication for weight loss, positioning the Danish pharmaceutical giant for what analysts describe as a "must-win" battle in the increasingly competitive obesity treatment market. The approval of Wegovy

Biotechnology

Omeros Breaks New Ground with First-Ever TA-TMA Therapy Launch

Omeros Corporation launches YARTEMLEA, the first and only FDA-approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), offering hope to thousands of patients facing a condition with mortality rates exceeding 90% in severe cases.

Biotechnology

Insilico's $292 Million IPO Marks Watershed Moment for AI-Driven Drug Discovery

Insilico Medicine completes Hong Kong's largest biotech IPO of 2025, raising $292 million and becoming the first AI-driven biotech company to list on the Hong Kong Stock Exchange's Main Board.

Biotechnology

Genetic Guardian: Rare Variant Offers 20% Protection Against Blood Cancers

A groundbreaking study published in Science has identified a rare genetic variant that acts as a natural shield against blood cancers, offering a 20% reduction in risk for those fortunate enough to carry it. The discovery not only illuminates why some people remain resilient against age-related blood malignancies but also

Biotechnology

Atara Biotherapeutics' Second Chance: January 10 FDA Decision Could Mark Historic First for EBV+ PTLD Treatment

Atara Biotherapeutics faces a critical FDA decision on January 10, 2026, for Tabelecleucel, which could become the first approved treatment for EBV+ PTLD, a rare cancer affecting transplant patients.

Pharmaceuticals

Sobi's $1.5 Billion Arthrosi Acquisition Signals Major Consolidation in Gout Treatment Market

Swedish Orphan Biovitrum (Sobi) acquires Arthrosi Therapeutics for up to $1.5 billion, positioning itself as a major player in next-generation gout treatment with pozdeutinurad.

Biotechnology

BioAtla's $40 Million Partnership May Signal a New Era for Precision Cancer Therapeutics

BioAtla's $40 million partnership with GATC Health to advance ozuriftamab vedotin into Phase 3 trials represents a sophisticated evolution in biotech financing and precision cancer therapeutics, with implications for both oncology and longevity research.

Biotechnology

T-MAXIMUM's Allogeneic CAR-T Breakthrough: FDA Clears Path for Glioblastoma Treatment Revolution

T-MAXIMUM Pharmaceutical's MT027 receives FDA IND clearance for Phase II trials, marking a potential breakthrough in allogeneic CAR-T therapy for solid tumors and glioblastoma treatment.

Pharmaceuticals

January 2026 FDA Decisions: Five Critical Approvals That Could Transform Patient Care

January 2026 marks a pivotal month for pharmaceutical innovation with five critical FDA decisions that could transform patient care across rare diseases, oncology, and ophthalmology.

Biotechnology

Ultragenyx's $1 Billion Wipeout Exposes the Harsh Realities of Rare Disease Drug Development

The final days of 2025 delivered a devastating blow to Ultragenyx Pharmaceutical as the company lost over $1 billion in market value following the failure of its bone disease therapy setrusumab in two pivotal Phase III trials. The December 29 announcement that the drug failed to reduce fracture rates in

Pharmaceuticals

Vanda Pharmaceuticals Surges on VVX-001 Breakthrough Designation and European Partnership

Vanda Pharmaceuticals surged 25.46% following FDA's Breakthrough Therapy Designation for VVX-001 and a strategic European partnership, signaling major progress in psychedelic-assisted therapy for treatment-resistant depression.